In recent years, China has become a global leader in oncology and immunology innovation and a key player in the commercial market for multinational pharma, yet it remains a persistent CI blind spot. Early clinical signals are often buried in only the China-based platforms and investigator-led trials, leaving Western CI teams exposed to delayed insights and reactive decision-making.
Standard global frameworks fail to capture the realities of the China market, including unique access dynamics, rapid regulatory evolution and an intensifying Western race to license or acquire breakthrough assets, all set against shifting geopolitical pressures.
This session sets out a practical framework to move China from a regional afterthought to a central pillar of global CI capability, actively driving insights and strategic decisions.
Jatin Gupta, Vice President, Prescient Health
